Alnylam to Webcast Conference Call to Discuss Takeda Alliance

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), announced today that the

company will hold a conference call on Tuesday, May 27 at 8:30 a.m. ET

to discuss its alliance with Takeda announced this morning. Conference Call Information The call may be accessed by dialing 800-329-9097 (domestic) or

617-614-4929 (international) five minutes prior to the start time and

providing the passcode 36634290. A replay of the call will be available

from 2:00 p.m. ET May 27, 2008 until June 3, 2008. To access the replay

please dial 888-286-8010 (domestic) or 617-801-6888 (international) and

provide the passcode 90685470. A live audio webcast of the call will

also be available on the "Investors" section of the company´s website, www.alnylam.com.

An archived webcast will be available on the Alnylam website

approximately two hours after the event, and will be archived for 14

days thereafter. About Alnylam Pharmaceuticals Alnylam is a biopharmaceutical company developing novel therapeutics

based on RNA interference, or RNAi. The company is applying its

therapeutic expertise in RNAi to address significant medical needs, many

of which cannot effectively be addressed with small molecules or

antibodies, the current major classes of drugs. Alnylam is leading the

translation of RNAi as a new class of innovative medicines with

peer-reviewed research efforts published in the world´s

top scientific journals including Nature, Nature Medicine

and Cell. The company is leveraging these capabilities to build a

broad pipeline of RNAi therapeutics; its most advanced program is in

Phase II human clinical trials for the treatment of respiratory

syncytial virus (RSV) infection. In addition, the company is developing

RNAi therapeutics for the treatment of a wide range of disease areas

including hypercholesterolemia, liver cancers, and Huntington´s

disease. The company´s leadership position in

fundamental patents, technology, and know-how relating to RNAi has

enabled it to form major alliances with leading companies including

Medtronic, Novartis, Biogen Idec, Roche, and Takeda. To reflect its

outlook for key scientific, clinical, and business initiatives, Alnylam

has established "RNAi 2010" which includes the company´s plan to

significantly expand the scope of delivery solutions for RNAi

therapeutics, have four or more programs in clinical development, and to

form four or more new major business collaborations, all by the end of

2010. Alnylam is a joint owner of Regulus Therapeutics LLC, a joint

venture focused on the discovery, development, and commercialization of

microRNA therapeutics. Founded in 2002, Alnylam maintains headquarters

in Cambridge, Massachusetts. For more information, visit www.alnylam.com.